focus -WSS

focus

author：fashion 2025-09-27 23:31:51 - browse：41

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Will.i.am, Britney Spears release new single, 'Mind Your Business'

WSS

Think you might have Covid

Artificial intelligence advances fuel industry trying to preserve loved ones after death

Independent physicians launch a new lobbying group

In new study, freeze

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Our daughter's deadly disease: trisomy 18. We wanted to protect her

focus

focus

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medicare Advantage today, explained in one chart

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Elizabeth Holmes banned from government health programs

Psychedelics group wrestles with new pharma identity

CDC backtracks, saying fully vaccinated people can go maskless indoors

As demand for Covid shots wanes, Moderna seeks its next success

AI generated plenty of interest at JPM but not a lot of trust

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

hotspot

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

EU regulator recommends expanding Mounjaro approval to obesity

Review: 'Barbie' will hit you like a shot in the heart

My yearlong odyssey to get my son’s ADHD medication covered

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Elizabeth Warren probes abortion access

focus

focus

Wikipedia

leisure time